Key Points
- CFO Erick Lucera sold 1,991 shares at an average $16.82, totaling about $33,489, to cover tax withholding on vested equity awards. He retained 117,775 shares after the transaction.
- Dyne reported a quarterly loss of $1.06 per share, missing analyst expectations of a $0.91 loss; the stock was reported down 2.7% and opened at $16.70.
- Analysts’ consensus rating was Moderate Buy, with an average price target of $31.29. Dyne remains a clinical-stage biotech with therapies in development and no approved products.
Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) CFO Erick Lucera sold 1,991 shares of the stock in a transaction on Friday, November 13th. The stock was sold at an average price of $16.82, for a total transaction of $33,488.62. Following the sale, the chief financial officer directly owned 117,775 shares in the company, valued at $1,980,975.50. This trade represents a 1.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Dyne Therapeutics Stock Down 2.7%
DYN stock opened at $16.70 on Tuesday. Dyne Therapeutics, Inc. has a one year low of $14.00 and a one year high of $27.31. The company has a debt-to-equity ratio of 0.21, a quick ratio of 12.99 and a current ratio of 12.99. The firm's fifty day moving average is $16.81 and its 200 day moving average is $19.32. The firm has a market cap of $3.13 billion, a PE ratio of -4.60 and a beta of 1.22.
Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($1.06) earnings per share for the quarter, missing analysts' consensus estimates of ($0.91) by ($0.15). During the same period last year, the business posted ($0.76) EPS. On average, research analysts forecast that Dyne Therapeutics, Inc. will post -3.81 EPS for the current year.
Wall Street Analyst Weigh In
DYN has been the subject of several recent analyst reports. HC Wainwright cut their price target on Dyne Therapeutics from $50.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, September 30th. Morgan Stanley lowered their price target on Dyne Therapeutics from $45.00 to $36.00 and set an "overweight" rating on the stock in a research report on Wednesday, September 9th. Piper Sandler reissued an "overweight" rating and issued a $47.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 29th. Chardan Capital reissued a "buy" rating and issued a $38.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, September 30th. Finally, Cantor Fitzgerald restated a "buy" rating on shares of Dyne Therapeutics in a research report on Wednesday, September 30th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $31.29.
Check Out Our Latest Analysis on Dyne Therapeutics
Hedge Funds Weigh In On Dyne Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company acquired a new position in shares of Dyne Therapeutics during the second quarter valued at approximately $1,746,000. Handelsbanken Fonder AB purchased a new position in shares of Dyne Therapeutics in the second quarter valued at approximately $1,182,000. Palo Alto Investors LP acquired a new stake in shares of Dyne Therapeutics in the second quarter worth approximately $36,591,441. Flputnam Investment Management Co. acquired a new stake in shares of Dyne Therapeutics in the second quarter worth approximately $1,177,000. Finally, Royal Bank of Canada increased its position in shares of Dyne Therapeutics by 267.6% during the first quarter. Royal Bank of Canada now owns 68,188 shares of the company's stock worth $1,236,000 after purchasing an additional 49,641 shares in the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.
Dyne Therapeutics Company Profile
(
Get Free Report)
Dyne Therapeutics is a clinical-stage biotechnology company developing therapies for genetically driven muscle diseases. Its research uses the FORCE platform, which is designed to deliver oligonucleotide medicines to muscle tissue. The company's programs include DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients whose genetic mutations are amenable to exon 51 skipping. Dyne has also pursued a program for facioscapulohumeral muscular dystrophy. Its therapies remain in development, and the company does not have an approved product.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].